Table 2 Small molecule inhibitors under clinical investigation
Target | Agent | The National Clinical Trial number | Year of completion |
|---|---|---|---|
EGFR, VEGFR, FGFR | Apatinib | NCT02874651 | Completed, 2020–08 |
NCT04586088 | 2023–09 | ||
NCT04350190 | Completed, 2022–09 | ||
NCT03180476 | Completed, 2020–04 | ||
NCT05549466 | 2025–09 | ||
Anlotinib | NCT03639467 | 2023–08 | |
NCT05232552 | 2024–12 | ||
NCT03906058 | Completed, 2022–04 | ||
NCT05981157 | 2025–12 | ||
NCT05807880 | 2025–10 | ||
Surufatinib | NCT04955886 | 2023–08 | |
Sorafenib | NCT02035527 | Completed, 2017–04 | |
Donafenib | NCT02698111 | Terminated, 2021–10 | |
PI3K | IPI-549 | NCT03795610 | 2023–06 |
BKM120 | NCT02113878 | Completed, 2022–01 | |
NCT01816984 | Completed, 2020–09 | ||
PARP | Fluzoparib | NCT04978012 | 2025–12 |
Niraparib | NCT05162872 | 2023–10 | |
HDAC | Nanatinostat | NCT05166577 | 2025–10 |
mTOR | RAPA-201 | NCT05144698 | 2024–12 |
CDK4/6 | Dalpiciclib | NCT05724355 | 2024–10 |
EBNA1 | VK-2019 | NCT04925544 | 2026–02 |